HANHUI
LIVE

Serial Number

79307453

Owner

HANHUI PHARMACEUTICALS CO., LTD.

Attorney

Christine P. James

Filing Date

Jan 30, 2021

Add to watchlist:

No watchlists yet
View on USPTO

HANHUI Trademark

Serial Number: 79307453 • Registration: 6770020

HANHUI is a trademark filed by HANHUI PHARMACEUTICALS CO., LTD. on January 30, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

HANHUI PHARMACEUTICALS CO., LTD. (5 trademarks)

NO. 2 HAIZHENG ROAD
HANGZHOU CITY, ZHEJIANG PROVINCE , CN

Entity Type: 16

Trademark Details

Filing Date

January 30, 2021

Registration Date

June 28, 2022

Published for Opposition

April 12, 2022

Goods & Services

Pharmaceutical preparations for use in chemotherapy, radiotherapy, endocrine therapy, anesthesia; Pharmaceutical preparations for supplementing vitamins and nutrition, namely, dietary and nutritional supplements; Pharmaceutical preparations for anti-infection and antiviral purposes; Pharmaceutical preparations for improving lactation functions; Pharmaceutical preparations for treating hematological diseases, namely, anemia, leucocyte disorders, blood clots; Pharmaceutical preparations for treating cardiovascular and cerebrovascular diseases, namely, blood lipid disorder, blood pressure disorder, arrhythmia, cardiac insufficiency, angina pectoris, myocardial infarction; Pharmaceutical preparations for treating respiratory system diseases, namely, phlegm, cough, asthma; Pharmaceutical preparations for treating digestive system diseases and disorders, namely, peptic ulcer, diarrhea; Pharmaceutical preparations for treating central nervous diseases and disorders, namely, fever and pain, gout, epilepsy, Parkinsonian syndrome, psychotic disorders, depression, anxiety, mania; Pharmaceutical preparations for treating geriatric diseases, namely, hyperosteogeny, prostatic hyperplasia, senile cataract; Pharmaceutical preparations for treating genitourinary system diseases, endocrine and metabolic system diseases and disorders, allergies, immune system diseases and disorders, liver and gall diseases, Alzheimer's diseases, skin diseases and disorders, obstetric and gynecological diseases and disorders, diseases with eye, ear, nose, mouth, oral cavity, and throat; Chemical preparations for pharmaceutical and medical purposes, namely, antineoplastic drugs, antibiotics, anti-infectives, vitamins and nutritional supplements, anesthetics, and those for treating hematological system diseases, cardiovascular and cerebrovascular diseases, endocrine and metabolic diseases and disorders, respiratory system diseases, digestive system diseases and disorders, central nervous system diseases and disorders, dermatological diseases, obstetric and gynecological diseases and disorders, ophthalmology and otorhinolaryngology diseases, and geriatric diseases; Analgesics; Medicines for humans, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and medicines for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system, eye, ear, mouth, and throat; Sedatives; Tranquillizers; Biological preparations for medical purposes, namely, vaccines, antineoplastic preparations, antitoxin, and antisera; Antibiotics; Injectable pharmaceuticals, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and those for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, ophthalmology and otorhinolaryngology diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system; Tablets, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and tablets for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, ophthalmology and otorhinolaryngology diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system; Bulk medicines, namely, antineoplastic drugs, anti-infectives, antibiotics, anesthetics, vitamin and nutritional supplements, and medicines for the treatment of allergy, cardiovascular and cerebrovascular diseases, dermatological diseases, geriatric diseases, ophthalmology and otorhinolaryngology diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, central nervous system, obstetrics and gynecology system; Biochemical medicines, namely, antineoplastic drugs, anti-infectives, antibiotics, and medicines for the treatment of allergy, cardiovascular and cerebrovascular diseases, and diseases with hematological system, genitourinary system, endocrine and metabolic system, immune system, respiratory system, digestive system, and central nervous system; Blood for medical purposes; Herbal tinctures for medical purposes; Diagnostic preparations for medical purposes; Chemical reagents for medical or veterinary purposes; Radium for medical purposes; Radioactive substances for medical purposes; Isotopes for medical purposes; Radioactive medicines for medical imaging and the treatment of tumor and thyroid diseases; Oxygen for medical purposes; Chemical conductors for electrocardiograph electrodes; Semen for artificial insemination; Disinfectants for hygiene purposes; Disinfectants; Solutions for contact lenses; Contact lens cleaning preparations; Media for bacteriological cultures; Bouillons for bacteriological cultures; Bacteriological culture mediums; Nutritive substances for microorganisms for medical purposes; Cultures of microorganisms for medical and veterinary use; Disinfectant wipes; Wadding for medical purposes; Food for babies

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Apr 9, 2023 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 1, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 6, 2022 FICS
FINAL DISPOSITION PROCESSED
Oct 6, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 28, 2022 FICR
NEW REPRESENTATIVE AT IB RECEIVED
Aug 21, 2022 NREP
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 28, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 28, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 12, 2022 NPUB
PUBLISHED FOR OPPOSITION
Apr 12, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 23, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 8, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 8, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 8, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 8, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 8, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 3, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 2, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 2, 2022 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 28, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 28, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 28, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 28, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 28, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 28, 2022 COAR
REFUSAL PROCESSED BY IB
Sep 20, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 28, 2021 RFCS
REFUSAL PROCESSED BY MPU
Aug 28, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 24, 2021 RFCR
NON-FINAL ACTION WRITTEN
Aug 23, 2021 CNRT
ASSIGNED TO EXAMINER
Aug 19, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 30, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 26, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 25, 2021 REPR